Last reviewed · How we verify

ketamine venlafaxine — Competitive Intelligence Brief

ketamine venlafaxine (ketamine venlafaxine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist, SNRI. Area: Psychiatry.

phase 3 NMDA receptor antagonist, SNRI NMDA receptor, SERT, NET Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

ketamine venlafaxine (ketamine venlafaxine) — University Hospital, Grenoble. Ketamine is an NMDA receptor antagonist, while venlafaxine is a serotonin-norepinephrine reuptake inhibitor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ketamine venlafaxine TARGET ketamine venlafaxine University Hospital, Grenoble phase 3 NMDA receptor antagonist, SNRI NMDA receptor, SERT, NET

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist, SNRI class)

  1. University Hospital, Grenoble · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ketamine venlafaxine — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-venlafaxine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: